Tacrolimus ointment:An Open study for Effects on Severe Facial Atopic Dermatitis in Korean

2002 ◽  
Vol 14 (4) ◽  
pp. 195 ◽  
Author(s):  
Won Woo Choi ◽  
Pan Gyo Seo ◽  
Kyu Han Kim
Keyword(s):  
Atopic Dermatitis ◽  
Open Study

An open study of a lotion formulation to improve tolerance of tacrolimus in facial atopic dermatitis

2001 ◽  
Vol 145 (5) ◽  
pp. 795-798 ◽  
Author(s):  
H. Sugiura ◽  
M. Uehara ◽  
N. Hoshino ◽  
A. Yamaji
Keyword(s):  
Atopic Dermatitis ◽  
Open Study

An open study to assess the efficacy clinically and immunologically ofM. vaccaevaccine in patients with atopic dermatitis

2006 ◽  
Vol 17 (2) ◽  
pp. 74-77 ◽  
Author(s):  
Michael G. Davies ◽  
Christine Symons ◽  
Stephen Shaw ◽  
Eduardo R. Kaminski
Keyword(s):  
Atopic Dermatitis ◽  
Open Study

Treatment of Severe or Resistant Corticosteroid-Responsive Dermatoses with Diprolene® Cream

1984 ◽  
Vol 12 (3) ◽  
pp. 163-169 ◽  
Author(s):  
M E Cabrera
Keyword(s):  
Atopic Dermatitis ◽  
Severity Score ◽  
Open Study ◽  
Plasma Cortisol ◽  
Therapeutic Response ◽  
Local Reaction ◽  
Signs And Symptoms ◽  
Additional Treatment ◽  
Normal Limits ◽  
The Mean

In an open study Diprolene®* Cream was administered to fifty patients with severe or resistant psoriasis, atopic dermatitis or other corticosteroid-responsive dermatoses. For a period of 14 days, patients applied 3·5 grams of medication twice daily. Efficacy was evaluated in forty-six patients, while tolerance and safety were evaluated in fifty patients. Therapeutic response in forty-one of forty-six patients was noted by treatment Day 3. By Day 14, mean total severity score of signs and symptoms in twenty-one patients with psoriasis was reduced by 88%. Similarly, in twenty-five patients with other severe or resistant corticosteroid-responsive dermatoses, a 99% decrease in the mean total severity score of signs and symptoms was evident. Of the patients evaluable for tolerance and safety, twenty-four of fifty reported transient, mild to moderate burning that occurred most often upon application of the study preparation. Therapy was not discontinued in any of these patients, and none required additional treatment for the local reaction. Morning plasma cortisol levels in monitored patients remained within normal limits throughout the study.

scholarly journals Influence of a Diester Glucocorticoid Spray on the Cortisol Level and the CCR4+ CD4+ Lymphocytes in Dogs with Atopic Dermatitis: Open Study

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Masato Fujimura ◽  
Hironobu Ishimaru
Keyword(s):  
Atopic Dermatitis ◽  
Cortisol Level ◽  
Peripheral Blood ◽  
Open Study ◽  
Serum Cortisol ◽  
Significant Suppression ◽  
Group I ◽  
Before And After ◽  
Group Ii ◽  
Gland System

This study investigated the influence of 0.00584% hydrocortisone aceponate spray (HCA; Cortavance Virbac SA, Carros, France) on blood serum cortisol levels and peripheral blood CCR4+ CD4+ T-lymphocyte levels in dogs with atopic dermatitis. Patients were randomly divided into group I (N=8) and group II (N=8). The dogs in group I were sprayed with HCA on the affected skin once a day for three weeks. The dogs in group II were treated once a day for 3 days followed by no treatment for 4 days for a total of three weeks. For the dogs in group I and group II the CADESI-03 scores before and after use of HCA showed significant reduction (P<0.01). The postcortisol level after the use of HCA in group I showed 36.0% decrease and showed significant suppression (P<0.01). By comparison, the use of HCA on group II did not show decrease in postcortisol levels. There was a tendency of suppression for hypothalamus—pituitary gland—adrenal gland system, but it was not serious influence. In addition, there was no influence on peripheral blood CCR4+ CD4+ lymphocytes percentage in dogs in group I after treatment with HCA.Corrigendum to “Influence of a Diester Glucocorticoid Spray on the Cortisol Level and the CCR4+ CD4+ Lymphocytes in Dogs with Atopic Dermatitis: Open Study”

Efficacy of Topical Calcineurin Inhibitors in Psoriasis

2014 ◽  
Vol 18 (1) ◽  
pp. 8-14 ◽  
Author(s):  
Cong Wang ◽  
Andrew Lin
Keyword(s):  
Atopic Dermatitis ◽  
Open Study ◽  
English Language ◽  
Calcineurin Inhibitors ◽  
Special Role ◽  
Double Blind ◽  
Topical Tacrolimus ◽  
Topical Calcineurin Inhibitors ◽  
Cutaneous Atrophy

Background: Topical calcineurin inhibitors (tacrolimus and pimecrolimus) are indicated for the treatment of atopic dermatitis but ve also been studied in the treatment of psoriasis. Objective: To define the efficacy of topical calcineurin inhibitors in the treatment of psoriasis. Methods: We searched for English-language articles published since 1990 in PubMed, Ovid/Cochrane, and Embase using “tacrolimus,” “pimecrolimus,” or “topical calcineurin inhibitors” and “psoriasis.” Results: Nine double-blind and 13 open studies demonstrated the efficacy of topical tacrolimus in psoriasis, especially for facial, genital, and intertrigious psoriasis, and four double-blind and one open study demonstrated the efficacy of topical pimecrolimus. Conclusions: The evidence (double-blind and open studies) is strong that topical tacrolimus and, to a lesser extent, pimecrolimus have efficacy in the treatment of psoriasis. Since these agents do not cause cutaneous atrophy, they likely have a special role in facial, genital, and intertriginous psoriasis. Further studies would help define their roles in psoriasis.

Sign in / Sign up

Export Citation Format

Share Document